Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study
Authors:
- F. GiottaFGF. Giotta
- E. MaielloEME. Maiello
- M.R. ValerioMVM.R. Valerio
- A. LatorreALA. Latorre
Open Access
- 1 June 2007
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 18 (suppl_6) , vi66-vi69
Abstract
Background: The objective of this study is to evaluate the efficacy and toxicity of the liposome-encapsulated doxorubicin (TLC D-99) plus cyclophosphamide (CTX) as first-line treatment of metastatic breast cancer in light of the potential cardioprotective effect of TLC D-99 as compared with conventional doxorubicin. Materials and methods: Sixty-seven patients as defined according Simon's two-stage phase II design were enrolled. They received TLC D-99 at the dosage of 60 mg/m 2 plus CTX 600 mg/m 2 , with cycles repeated every 3 weeks. Cardiac function was assessed by ultrasonography at baseline and every two cycles. Results: The principal characteristics of the 67 enrolled patients were as follows: median age 60 years (range 33–75), median World Health Organization performance status of 1 (range 0–2) and dominant disease site (viscera/bone/soft tissue): 47/15/15 There were nine complete responses and 32 partial responses for an overall response rate of 64%; a further 14 patients had stable disease and the remaining nine patients progressed. Median number of administered cycles was six. Median duration of response was 10 and 9 months, respectively, for complete responders and partial responders. Median duration of survival was 17+ months (range 3 to 33+). Hematological toxicity consisted in leucopenia (G1–G2) in 21 patients and anemia (G1–G2) in 20 patients; G1 thrombocytopenia was observed only in 2 patients. Non-hematological toxicity was generally mild with G1–G2 nausea/vomiting in 23 patients and G1–G2 mucositis in 10. Hair loss was registered in 30 patients and it was G2 in 14 patients. As to concern cardiac toxicity, one patient developed an asymptomatic 20% decline of left ventricular ejection fraction from the baseline value. Conclusions: The results of our study show that the combination of TLC D-99 plus CTX is active and well tolerated, with no unexpected toxicity.Keywords
This publication has 11 references indexed in Scilit:
- Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer.Cancer Research, 2009
- Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trialAnnals of Oncology, 2005
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 2001
- Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparisonThe Breast, 2001
- Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- Reporting results of cancer treatmentCancer, 1981
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- A clinicopathologic analysis of adriamycin cardiotoxicityCancer, 1973